TAG ARCHIVES FOR DEIJ

19
Jan2021

Last year, Heather H. Pierce, JD, MPH and I shared some thoughts about the Belmont Report at 40, and about the evolution and flexibility of the Belmont principles of respect for persons, beneficence, and justice in the face of changing circumstances. As we leave behind the extraordinary year of 2020, I have been thinking about how the pandemic, together with the Black Lives Matter social justice movement, has shone new, and I would say welcome, light on the principle of justice in research. Read more

3
Nov2020

Amid both promising and worrying signs in the development of treatments and vaccines for COVID-19, and in the context of a considerable amount of scrutiny of medical research, some researchers, ethicists, and advocates are working to make sure science doesn’t lose sight of a critical issue: diversity in the clinical trial participant pool. The distribution of research benefits to participants—and the consideration of race in subject selection—is tightly woven into the Belmont Report and has been a mainstay in research ethics discussion ever since. But despite the decades-long consideration of race and ethnicity in clinical trials, many trials still don’t enroll populations that reflect the diversity of the general populace or the group affected by the condition being studied. Read more

29
Jul2020

In this edition of Research Ethics Reading List, we feature books on the intersection of race and research ethics. (Book description copy comes courtesy of each book’s publisher or author website where possible.)

Just Medicine: A Cure for Racial Inequality in American Health Care
Dayna Bowen Matthew

“Over 84,000 black and brown lives are needlessly lost each year due to health disparities: the unfair, unjust, and avoidable differences between [...] Read more

7
Jul2020

COVID-19 has taken the lives of more than 120,000 people in the United States and debilitated millions more since arriving on our shores. While anyone can contract the virus, there is a pattern to who gets sick and dies from it here. Yet very few of the Tech Sector’s responses to the disease seem to acknowledge — let alone respond to — this fact. Read more